Pages: 77 - 79
Authors: Musabaeva N. E., Bayjanov A. K.
Abstract: The research has been aimed at studying of a degree of incidence of the opportunistic and associated diseases in patients with natural course of the HIV-infection. Development of a number of opportunistic diseases is the basic indicator of HIV-infection progression. Up to date, there are a number of scientific papers dedicated to studying of the opportunistic infections [1; 2]. Among the HIV-infected patients, tuberculosis  is mainly developed infection out of the opportunistic infections, which is one of the basis reasons for patients’ death rate. The risk of tuberculosis reactivation in the HIV-infected patients with positive tuberculine test is 7–10% within a year, and 20–70% of new cases of active tuberculosis in the developing countries. Virus infections (CMV, virus hepatitis С, etc.) [4; 7] also have active influence on the immune system. It is known that the opportunistic diseases under the HIV-infection mutually aggravate the immune system state at the same time facilitating fast transition of the HIV-infection to the end stage of the disease. This is why there is a need to study a spectrum of the opportunistic diseases for the purpose of timely therapy of both the region-specific opportunistic diseases and the HIV-infection [5; 6; 8; 9].
Keywords: opportunistic diseases, chronic virus hepatitis В, С and D, cytomegalovirus infection, tuberculosis, lymphoma, chorioretinitis, pneumocystic pneumonia
1. Buchacz K. AIDS-defining opportunistic illnesses in US patients, – 1994–2007: A cohort study. AIDS – 2010. Jun 19; 24:1549.
2. Bushman F. D., Nabel G. J., Swanstrom R. HIV: From biology to prevention and treatment. – Cold Spring Harbor, New York, USA:
Cold Spring Harbor Laboratory Press, – 2012. – Р. 321–343.
3. Clark P. M., Karagoz Т., Apikogly-Rabus S., Izzettin F. V. Effect of pharmacist-led patient education on adherence to tuberculosis treatment//
Amer. J. Health-System Pharmacy. – 2007. – Vol. 64, N 5. – P. 497–505.
4. Duerst R. Innate immunity to herpes simplex virus type 2//Viral immunology – 2003 – Vol. 16, № 4 – P. 475–490.
5. Friedrich B. M., Dziuba N., Li G. et. Host factors mediating HIV‑1 replication. Virus Res. – 2011 Nov; 161 (2): 101–14.
6. Hall J. C., Hall B. J., Cockerell C. J. HIV/AIDS in the post-HAART era: Manifestations, treatment, and epidemiology. – Shelton, CT,
USA: People’s Medical Publishing House – USA, – 2011. – Р. 389–403.
7. Joshi D., O’Grady J., Dieterich D. et al. Increasing burden of liver disease in patients with HIV infection. Lancet, – 2011; – 377: 1198–
8. Lever A. M., Jeang K. T. Insights into cellular factors that requlate HIV‑1 replication in human cells. Biochemistry. – 2011 Feb – 15;
9. Saag M. S., Chambers H. F., Eliopoulos G. M., Gilbert D. N., Moellering R. C. The Sanford guide to HIV/AIDS therapy – 2012. – Sperryville,
VA, USA: Antimicrobial Therapy Inc., – 2012. – Р. 214.